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We selected 63 prostate tumors with Gleason’s grade 6
(3+3), commonly showing both tubular and cribrous pat-
terns. We compared in both patterns the expression of two of
the most used biologic markers: PCNA and p53, with the aim
to verify the validity of the Gleason’s grading system to com-
pare the morphologic grade with biologic aggressiveness
and prognostic value. We did not find any statistical differ-
ence in the protein immunopositivity, indicating that both
patterns could have identical biologic behaviour; then we
confirmed the validity of Gleason’s system for considering
both tubular and cribrous patterns as an intermediate grade
of tumoral differentiation. Moreover, we found a linear rela-
tionship between the increase of PCNA and the accumula-
tion of mutated p53; this datum could confirm the hypothe-
sis that p53 mutation is a late event in prostate carcinogen-
esis.
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P
rostate adenocarcinoma is one of the most
frequent malignancy and the second leading
cause of cancer-related deaths in men in
Western Countries (Boring et al., 1992). It deter-
mined a great focus on its pathogenesis as well as
diagnostic and prognostic criteria and therapeutic
approach.
Gleason’s system is the most widely used grading
of prostate carcinoma, based on the tissue aspect at
low magnification (Gleason, 1977). The value is
obtained identifying the predominant and the second
most prevalent architectural pattern and assigning a
grade from 1 to 5, with 1 being the most differenti-
ated and 5 undifferentiated (Gleason, 1977).
The main advantages of this system are that i) it is
easy to learn and apply and ii) it was well demon-
strated its fairly well correlation with the prognosis
(Kramer et al., 1980). The most frequent causes of
pitfall are i) the multifocality of the prostate cancer
with simultaneous variety of differentiation and ii)
the tendency to undergraduate the bioptic material
when a minimal amount of tumor is present.The lat-
ter can determine difficulty in valuing the variability
of neoplastic gland size and shape, especially impor-
tant to identify the Gleason’s grade 3. Moreover, the
combination of tumoral grade with other prognostic
variables to determine multiple prognostic indexes
allows greater precision in predicting outcome
(Kramer et al., 1980).
Gleason 6 (3+3) is one of the most commonly
found grade. It is characterised by both tubular
and/or cribrous pattern of tumoral glands.
Commonly, adenocarcinomas of other sites with a
tubular pattern are thought a more differentiated
form then the cribrous ones, considering the latter as
an expression of an intermediate differentiation. On
the contrary, the presence of one (or both) of these
patterns in prostate adenocarcinoma, implies an
intermediate grade of differentiation. Nevertheless,
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to our knowledge, none study looked for the presence
of discrepancies between these two pattern in terms
of biologic characterisation and behaviour.
Here, we studied two important prognostic index-
es in a large series of Gleason 6 (3+3) prostate ade-
nocarcinomas: proliferating cell nuclear antigen
(PCNA) and p53. PCNA is retained one of the most
important index to estimate the tumoral proliferate
activity (proliferating index, PI), while p53 is the
widest studied tumor suppressor gene, involved in
regulation of cell cycle. The objective was to verify
the presence (or absence) of a discrepancy in the
expression of these antigens in both tubular and
cribrous patterns.
Materials and Methods
Files of the Institute of Pathology of the
University of Palermo were searched for cases of
prostate carcinoma, Gleason 6 (3+3), during the
period between 1st Jannuary 1998 and 31st
December 2001. All specimens were been formalin-
fixed and paraffin-embedded. We selected 63 cases,
in which there were simultaneously present tubular
and cribrous areas. Seven micrometers sections were
stained with H&E for routinely diagnosis. Moreover,
we performed an immunohistochemical analysis.
We immunostained with avidin-biotin complex
(LSAB2, DAKO), using primary antibodies against
PCNA (Clone PC10, DAKO, Cat. No. M 0879) and
p53 (Clone DO-7, Dako, Cat. No. M 7001) respec-
tively diluted at 1:50 and 1:40. Non-immune serum
was substituted for negative controls. Appropriate
positive controls were run concurrently for both anti-
bodies tested. Aminoethilcarbazol (AEC chromogen,
DAKO, Cat. No. K0697) was used as develop chro-
mogen. A light nuclear counterstaining with hema-
toxylin was finally performed.
To better confirm the data, the immunostainings
were repeated three times on two sections for each
specimen.Two independent observers carried out the
microscopical analysis.They valued: PCNA, counting
the percentage of positive tumoral cells in 10 HPF;
p53, counting the number of tumoral glands in which
at least one cell expressing antigenic positivity was
present in 10 HPF.
We using the One way analysis of variance
(ANOVA) to determine the presence of significant
differences within the data. Differences between the
means of the values were regarded as significant
when a p<0.05 was obtained. Moreover, we used the
“r-Pearson” model to verify the presence of a linear
relationship between PCNA and p53 immunopositiv-
ity (t-tab: 2,021).
Results
We observed 63 cases of prostate adenocarcinoma
with both cribrous and tubular pattern.Tumoral tis-
sue showed closely packed small glands, usually
irregularly separated, with poorly defined edge and
smoothly circumscribed masses of cribriform epithe-
lium (Figure 1a). Moreover, tumoral cells present in
the glands differed from surrounding benign tissue in
both cytoplasmic or nuclear features. In particular,
prominent nucleoli, nuclear enlargement, hyperchro-
matic nuclei, amphophilic cytoplasm and mitotic fig-
ures were common features (Figure 1b). In addition,
basal cells were frequently absent and corpora ami-
lacea were rare. Finally, high-grade PIN (prostatic
intraepithelial neoplasia) foci were occasionally
found in proximity of tumoral glands.
Immunohistochemistry demonstrated the presence
of PCNA in all examined specimens (100%), while
p53 was present only in 40 of 63 cases (63,5%). In
particular, the positivity of PCNA ranged between
20% and 55% of the tumoral cells (in mean 35%)
(Figure 1c), while p53 was expressed in a number of
tumoral glands varying between 0% and 45% (in
mean 14%) (Figure 1d). In addition, both PCNA
and p53 positivity were occasionally found in high-
grade PIN foci (0-5%), while normal glands showed
rare and negligible positivity only to PCNA (0-1%).
At the statistical analysis, no significative differ-
ence resulted in positivity between these two mark-
ers in both tubular and cribrous areas (p> 0.05). In
particular, we found PCNA positivity in mean in
34% of tubular area and 35% of cribrous area
cells, while p53 was found in mean in 13% and 15%
of tubular and cribrous glands, respectively.
Moreover, a linear relationship between PCNA and
p53 expression was found (t=2.235; t-tab=2.021;
t>t-tab), examining the 40 cases in which both
markers were simultaneously present (Figure 2).
Discussion
Proliferating cell nuclear antigen (PCNA) is one
of the most studied proliferation-associated protein.
It was demonstrated to be a strong sensitive indica-
tor of cellular growth fraction (PI), because it is
detectable throughout most of the cell cycle, during
active DNA synthesis or cell division (Hall et al.,
1990). Moreover,Visakorpi reported a strong corre-
lation between high level of PCNA staining and poor
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prognosis for patients with prostate carcinoma
(Visakorpi, 1992). In addition, Montironi et al.
(1993) showed that the number of PCNA-stained
nuclei increased from small and large acinar pat-
terns through cribriform to solid or trabecular pat-
terns. Moreover, there was also a tendency for a
stronger staining at the invasive edge of the neoplas-
tic area than in the central region.
P53 is a tumor suppressor gene frequently altered
in malignant human tumors (Oren, 1992; Cappello
et al., 2001). In case of DNA damage, functional
(wild) p53 may block cell-cycle progression in late
G1 phase or may trigger an intrinsic mechanism of
apoptosis (Levine et al., 1991, Cappello et al., in
press). By contrast, the abnormal p53 protein pro-
duced by mutant gene is ineffective and more stable
than the wild type protein; it becomes less sensitive
to proteolysis and it tends to accumulate in the
nucleus, so being easily detected by immunohisto-
chemistry (Brunner et al., 1993). We used the mon-
oclonal antibody clone DO-7 that recognised both
wild-type and mutant p53; however, because the wild
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Figure 1. Histologic and immunohis-
tochemical aspects of studied
tumors. A: H&E stained section
showing both patterns: tubular
(arrow) and cribrous (arrow-head),
103. B. H&E showing the features
of the tumoral cells, 403. C: PCNA
positivity in both tubular (arrow)
and cribrous (arrow-head) patterns,
103. D: cribrous area showing
nuclear positivity to p53. Inset:.p53








type protein is rapidly degraded, its physiologic lev-
els remain below the immunohistochemical
detectably threshold. In this way, p53 immunoreac-
tivity is likely to reflect p53 gene mutations
(Papadopoulos et al., 1996). Numerous studies sug-
gested the role of p53 mutation in the pathogenesis
of prostate cancer, even if recent studies reported
conflicting results about the incidence of nuclear
p53 accumulation (Samaan et al., 1993; Kallakury
et al., 1994; Fox et al., 1993; Shurbaji et al., 1995).
In our study, PCNA resulted positive in all cases,
with a mean percentage of 35% tumoral cells. By
contrast, p53 was present in 40 of 63 cases, with a
mean value of 14% of tumoral glands. It should
mean that the studied tumors had a moderate pro-
liferation index and an intermediate differentiation.
Moreover, we found a linear relationship between PI
and p53 positivity. This datum indicated a correla-
tion between the increase of proliferating index and
the accumulation of mutated p53. This is in agree-
ment with Papadopoulos et al. (1996) that found a
highly significant correlation between p53 over-
expression and tumor stage. They suggested the
mutation of the p53 gene was not an initial event in
prostate carcinogenesis. It implied the existence of a
strong correlation between p53 and tumor grade,
suggesting also that aberrant p53 expression goes
along with a loss of differentiation. Indeed,
Papadopoulos et al. (1996) found that tumors with
increased p53 positivity also exhibited a significant
higher proliferation index, this latter corroborating
the former observation. In conclusion, in this work
we studied a series of prostate adenocarcinomas
with an intermediate grade of differentiation
(Gleason 6: 3+3).There were simultaneously present
both tubular and cribrous areas. Generally, the pres-
ence of a tubular pattern in adenocarcinomas of
other sites than prostate addresses the diagnosis
towards a well-differentiated tumor, while the
cribrous aspect is commonly an index of intermedi-
ate differentiation. Notwithstanding this, we did not
find any statistic difference between PCNA and p53
expression in both tubular and cribrous patterns of
prostatic adenocarcinomas. Therefore, our results
confirmed the validity of the Gleason’s system to
attribute an intermediate grade of differentiation at
both tubular and cribrous patterns.
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